Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: Evidence from secondary analysis of an English primary care audit survey by Lyratzopoulos, G et al.
Gender inequalities in the promptness
of diagnosis of bladder and renal
cancer after symptomatic presentation:
evidence from secondary analysis of an
English primary care audit survey
Georgios Lyratzopoulos,1 Gary A Abel,1 Sean McPhail,2 Richard D Neal,3
Gregory P Rubin4
To cite: Lyratzopoulos G,
Abel GA, McPhail S, et al.
Gender inequalities in the
promptness of diagnosis of
bladder and renal cancer after
symptomatic presentation:
evidence from secondary
analysis of an English
primary care audit survey.
BMJ Open 2013;3:e002861.
doi:10.1136/bmjopen-2013-
002861
▸ Prepublication history and
additional material for this
paper is available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-002861).
Received 11 March 2013
Accepted 29 April 2013
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered affiliations see
end of article.
Correspondence to
Dr Georgios Lyratzopoulos;
gl290@medschl.cam.ac.uk
ABSTRACT
Objectives: To explore whether women experience
greater delays in the diagnosis of bladder and renal
cancer when first presenting to a general practitioner
with symptoms caused by those cancers and potential
reasons for such gender inequalities.
Design: Prospective national audit survey of cancer
diagnosis.
Setting: English primary care (2009–2010).
Participants: 920 patients with bladder and 398
patients with renal cancer (252 (27%) and 165 (42%),
respectively, were women).
Primary and secondary outcome measures:
Proportion of patients with three or more pre-referral
consultations; number of days from first presentation
to referral; proportion of patients who presented with
haematuria and proportion of patients investigated in
primary care.
Results: Women required three or more prereferral
consultations more often than men (27% (95% CI
21% to 33%) vs 11% (9% to 14%) for bladder
(p<0.001); and 30% (22% to 39%) vs 18% (13% to
25%) for renal cancer (p=0.025)) and had a greater
number of days from presentation to referral. In
multivariable analysis (adjusting for age, haematuria
status and use of primary care-led investigations),
being a woman was independently associated with
higher odds of three or more pre-referral consultations
(OR=3.29 (2.06 to 5.25, p<0.001) for bladder cancer;
and OR=1.90 (1.06 to 3.42, p=0.031) for renal
cancer). Although presentation with haematuria was
associated with more timely diagnosis of bladder
cancer, gender inequalities did not vary by haematuria
status for either cancer (p=0.18 for bladder and
p=0.27 for renal). Each year in the UK, approximately
700 women with either bladder or renal cancer
experience a delayed diagnosis because of their
gender, of whom more than a quarter (197, or 28%)
present with haematuria.
Conclusions: There are notable gender inequalities in
the timeliness of diagnosis of urological cancers.
There is a need to both reinforce existing guidelines
on haematuria investigation and develop new
diagnostic decision aids and tests for patients who
present without haematuria.
ARTICLE SUMMARY
Article focus
▪ Limited previous evidence suggests that women
with urinary tract cancers may be diagnosed less
promptly than men with the same cancers.
▪ Evidence is needed from contemporary clinical
data sources to establish whether gender
inequalities do exist, their magnitude, and their
potential causes.
Key messages
▪ Women with bladder and renal cancer are more
likely than men to require three or more prerefer-
ral consultations with a general practitioner, and
to experience longer time intervals between pres-
entation and hospital referral.
▪ There were gender differences for patients both
with and without haematuria, suggesting that
doctors often interpret the clinical importance of
haematuria differently in men and women.
▪ Population health impact estimates suggest that
gender inequalities can be reduced by reinforcing
existing clinical guidelines on haematuria man-
agement. However, new approaches (such as
use of clinical decision support tools) also need
to be developed to improve the diagnosis of
patients of either gender who present without
haematuria.
Strengths and limitations of this study
▪ We were able to explore potential confounding of
gender differences in diagnosis by gender differ-
ences in the management of haematuria or by
differential use of primary care-led investigations.
▪ We have estimated the population health impact
of the observed relative differences in the timeli-
ness of diagnosis.
▪ The sample size of the study was relatively small
(particularly for patients with renal cancer).
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INTRODUCTION
Promptly diagnosing patients who present with symp-
toms caused by cancer is a pressing priority for health-
care systems worldwide.1–5 Globally, most patients with
cancer first present to a non-specialist doctor (usually a
general practitioner), who has to appropriately suspect
the diagnosis in order to instigate an onward referral to
a specialist. Some diagnostic delays therefore occur after
presentation to a general practitioner,6 because signs
and symptoms are initially attributed to a benign cause.
Patients with certain sociodemographic characteristics
may be at higher risk of experiencing a less prompt spe-
cialist referral.7 8 Avoiding delays in diagnosis after pres-
entation to a doctor is an important determinant of
patient experience and matters greatly to all patients
and their carers.9–12
In England, uniquely pronounced gender inequalities
in relative survival from bladder cancer exist, with 5-year
relative survival for men being 57%, compared with 44%
for women.13 Further, specifically for bladder and renal
cancer (and using English patient-reported data),
notable gender inequalities have been reported in the
number of times patients had to see their general practi-
tioner with cancer symptoms before referral to a special-
ist (table 1).8 A US study also showed that women
presenting with haematuria to a primary care physician
are referred to a urologist for investigation less promptly
than men.14 Misattribution of symptoms of urinary tract
cancers in women to benign urogenital causes (eg,
urinary tract infection) has been hypothesised as the
reason for these gender differences,8 but several uncer-
tainties remain: are gender differences in the number of
pre-referral consultations apparent when using data
sources other than patient surveys? Do differences in the
number of prereferral consultations translate to differ-
ences in the time interval between first presentation and
specialist referral? Could at least some of the gender dif-
ferences in the promptness of diagnosis be explained by
differences in presenting signs and symptoms (particu-
larly haematuria)? Against this background, we set out
to examine gender differences in the promptness of
diagnosis of bladder and renal cancer.
METHODS
Data
We analysed data from the (English) National Audit of
Cancer Diagnosis in Primary Care (2009–2010).15 Data
on different aspects of the diagnostic process were col-
lected by general practitioners or other primary care pro-
fessionals in an estimated total of 1170 general practices
(∼14% of all practices in England). Details of the
methods used in the audit have been published previ-
ously.15 16 Although general practice participation was
voluntary, comparisons with cancer registration statistics
indicate that the data set is representative of the age, sex
and cancer type breakdown of patients with cancer in
England.15 Data were available on two interrelated mea-
sures of promptness of diagnosis,16 that is, the number of
prereferral consultations and the primary care interval
(ie, the time interval between the first symptomatic pres-
entation of a patient with cancer to a general practitioner
and their first specialist referral for further investigation,6
measured in days by subtracting the date of first hospital
referral from the date of first presentation). We used a
binary form of the number of prereferral consultations
(three or more vs one or two consultations) reflecting
the use of this outcome by both patient groups and UK
policy-makers for purposes of public reporting of the per-
formance of NHS hospitals.17 Data were also available for
patients’ 5 year age group, sex, main presenting symptom
and primary care investigations.
Analysis
Initial analysis was restricted to patients with at least one
recorded general practitioner consultation before hos-
pital referral and complete information on sex and age
group.
In univariable analysis, we examined crude gender dif-
ferences in promptness of diagnosis. We also described
gender differences in haematuria status and in use of
‘blood test’ and ultrasound scan investigations (as these
three factors have the potential to at least partially
explain gender differences in promptness of diagnosis).
Symptom analysis was restricted to macroscopic haema-
turia because it was the most common main presenting
Table 1 Gender differences in the promptness of diagnosis of urinary tract cancer (Cancer Patient Experience Survey,
2010)8
Patients who saw their
GP with cancer
symptoms (N)
Patients with
three or more GP
consultations
before hospital
referral (n)
Patients with three
or more GP
consultations
before hospital
referral (n/N=%)
Crude odds ratio
(95% confidence
interval)
Adjusted odds
ratio
(95% confidence
interval)
Bladder
Men 4254 624 14.7 Reference Reference
Women 1295 357 27.6 2.29 (1.97 to 2.67) 2.33 (1.99 to 2.72)
Renal
Men 391 103 26.3 Reference Reference
Women 208 77 37.0 1.63 (1.12 to 2.36) 1.65 (1.13 to 2.40)
GP, general practitioner.
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symptom, because of its singularly strong association
with urological cancers18–22 and because of the UK clin-
ical guidelines by the National Institute of Health and
Clinical Excellence (NICE) mandating urgent specialist
referral of patients who present with macroscopic
haematuria, independently of their gender (‘male or
female adult patients of any age who present with pain-
less macroscopic haematuria should be referred
urgently’).23 Hereafter, in this manuscript and tables,
the term ‘haematuria’ will denote macroscopic haema-
turia. Investigations were restricted to ‘blood test’ (not
otherwise specified in the data set) and ultrasound scan
because they were the only two commonly recorded
investigations (see online supplementary appendix 1).
Using multivariable logistic regression, we further
explored the association between the number of prereferral
consultations (three or more consultations vs one or two)
and gender. First, we examined to what extent gender dif-
ferences are confounded by other variables (age, haema-
turia status, ultrasound scan investigation, and ‘blood test’).
Subsequently, we used a final (‘full’) model including all
variables. We further explored interactions of gender by all
other variables. Because patients attend different practices,
we used a sandwich estimator of standard errors.
Sensitivity analysis
We first repeated the multivariable regression model
using different definitions of binary categories of the
number of prereferral consultations (two or more vs
one; and four or more vs one, two or three consulta-
tions). We further explored potential bias arising from
missing data, using multiple imputation to produce a
complete data set,24–27 and repeated the multivariable
analysis (outlined above). Multiple imputation assumes
that data are ‘missing at random’ (MAR), that is, that
any systematic differences between the missing and
observed values can be estimated using information
from the observed data. The imputation model included
all variables used in the analysis model and, in addition,
the primary care interval variable (as the primary care
interval is strongly correlated with the proportion of
three or more prereferral consultations16).
Population health impact
Assuming that the national audit data are generalisable
to contemporary UK practice, we illustrate the potential
population health impact of the findings. For this esti-
mation, we used a logistic regression model (three or
more vs one or two consultations) including age, gender
and haematuria status as covariates to predict the pro-
portion of men and women (with and without haema-
turia) who require three or more prereferral
consultations both in the presence and absence of
gender differences. When assuming no gender differ-
ences, we replace the odds ratio for gender by 1. The
obtained proportions are scaled using national inci-
dence statistics to give annual numbers for the UK. Stata
V.11 was used for all analyses, including the uses of ice
and mim commands for multiple imputation.28
RESULTS
In total, there were 920 patients with bladder cancer and
398 patients with renal cancer, of whom 252 (27%) and
165 (42%), respectively, were women—proportions
similar to contemporary UK population-based incidence
statistics (28% and 38%, respectively, for bladder and
renal cancer).29 Unless where noted, after exclusion of
patients whose diagnosis did not involve a prereferral
consultation and missing data (see online supplemen-
tary appendix 2), complete case analysis was restricted to
740 patients with bladder cancer and 287 patients with
renal cancer with at least one known prereferral consult-
ation. Among patients with bladder and renal cancer,
respectively, 91% and 85% were 55 years of age or older
(ie, older than the age by which most women would
have experienced their menopause) with no evidence of
gender differences in these proportions (p=0.77 and
p=0.76, respectively, for either cancer).
Univariable analysis
Women had longer primary care intervals compared
with men for both cancers (table 2) and required three
or more prereferral consultations more often than men
for either bladder (27% vs 11%, p<0.001) or renal
cancer (30% vs 18%, p=0.025, table 3). Although
gender differences in the median primary care interval
were relatively small (6 vs 4 days for bladder cancer and
16 vs 10 days for renal cancer), substantial differences
existed in the tails of the distribution. For either bladder
or renal cancer, the 75th centile in women was longer
than that in men by about 2 weeks (table 2) and at the
90th centile, the difference increased to over 2 months
Table 2 Centiles of the primary care interval by gender for bladder and renal patients with cancer
Bladder cancer (n=721) Renal cancer (n=271)
Centile Men (n=525) (days) Women (n=196) (days) p Value Men (n=160) (days) Women (n=111) (days) p Value
25th 0 0 0.0059 0 3 0.016
50th 4 6 10 16
75th 15 32.5 31 46
90th 39 103 64 82
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for bladder cancer and to about 3 weeks for renal
cancer.
About two-thirds of all patients with bladder cancer
and about one-quarter of all patients with renal cancer
had haematuria as the main recorded primary symptom
(table 3)—proportions similar to those previously
reported in relevant patient populations (see online sup-
plementary appendix 3).18 19 21
Multivariable analysis
Haematuria status was strongly related to having three or
more prereferral consultations but explained only a small
amount of the crude gender difference for either cancer
(table 4 and online supplementary appendix 4). Similarly,
there was no or a limited degree of confounding of the
gender association by the other three variables (see online
supplementary appendix 4). Using the full model, for
bladder cancer, we find that three or more prereferral con-
sultations were substantially more likely in women
(OR=3.29 (2.06 to 5.25, p<0.001, table 4)) and less likely
among those presenting with haematuria (OR=0.29 (0.19
to 0.46, p<0.001). For renal cancer, three or more prerefer-
ral consultations were more likely in women (OR=1.90
(1.06 to 3.42, p=0.031)) without evidence for an associ-
ation with haematuria (p=0.25).
Regarding interactions, there was no evidence that
gender differences in the proportion of patients with
three or more prereferral consultations varied between
patients with and without haematuria (p=0.18 for
bladder and p=0.27 for renal cancer), as well as by age
group (p=0.38 and p=0.10), ‘blood test’ use (p=0.71 and
p=0.91) or ultrasound scan use (p=0.20 and p=0.59).
Sensitivity analysis
Repeating the multiple logistic regression using different
binary categories of the number of prereferral consulta-
tions produced similar findings, particularly regarding
associations with gender and haematuria status.
Sensitivity analysis using multiple imputation of missing
data also produced similar findings (see online supple-
mentary appendices 5 and 6).
Population health impact
Each year in the UK, about 2900 women are diagnosed
with bladder cancer and 3000 with renal cancer.29 Of
those women, we estimate that each year approximately
693 (∼435 with bladder cancer and ∼258 with renal
cancer) experience three or more prereferral consulta-
tions when they would have required only one or two
had gender inequalities not been present (see online
supplementary appendix 7). More than a quarter (197,
or 28%) of those women experience gender inequalities
in the presence of haematuria.
DISCUSSION
In our study population, we found that women were
more likely than men to experience a non-prompt diag-
nosis of bladder and renal cancer. Being a woman was
an independent risk factor for a less timely diagnosis
even after adjustment for age and presence/absence of
haematuria or use of investigations. Moreover, differ-
ences in haematuria status between men and women
explain only a small fraction of the crude gender differ-
ences. The findings indicate that generalists are less
likely to suspect the diagnosis of urinary tract cancers in
Table 3 Univariable associations between gender and number of prereferral consultations, recorded haematuria,
investigation by ‘blood test’ and ultrasound scan
Bladder cancer (n=740) Renal cancer (n=287)
Men (n=538) Women (n=202) Men (n=169) Women (n=118)
n Per cent n Per cent p Value n Per cent n Per cent p Value
Number of prereferral consultations
1 320 59.5 102 50.5 <0.001 89 52.7 45 38.1 0.093
2 158 29.4 46 22.8 49 29.0 38 32.2
3 40 7.4 23 11.4 17 10.1 16 13.6
4 8 1.5 11 5.4 5 3.0 8 6.8
5+ 12 2.2 20 9.9 9 5.3 11 9.3
1–2 478 88.8 148 73.3 <0.001 138 81.7 83 70.3 0.025
3+ 60 11.2 54 26.7 31 18.3 35 29.7
Haematuria
Yes 394 73.2 143 70.8 0.51 57 33.7 23 19.5 0.008
No 144 26.8 59 29.2 112 66.3 95 80.5
Ultrasound scan
Yes 39 7.2 36 17.8 <0.001 44 26.0 35 29.7 0.50
No 499 92.8 166 82.2 125 74.0 83 70.3
Blood test
Yes 207 38.5 47 23.3 <0.001 71 42.0 45 38.1 0.510
No 331 61.5 155 76.7 98 58.0 73 61.0
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women and that haematuria is often interpreted differ-
ently by general practitioners depending on the patient’s
gender. Optimising referral decisions for women with
bladder and renal cancer who present with haematuria
may have a notable impact on gender inequalities in
promptness of diagnosis. However, many patients with
urinary tract cancers (both women and men) present
without haematuria. For those patients, new approaches
are needed to help improve the promptness of diagnosis
for patients of either gender.
Our findings amplify previous limited evidence on
gender inequalities in the diagnosis of urinary tract
cancers using patient-reported data in England and also
previous US research.8 14 The strengths of the present
study include the use of two different measures of prompt-
ness of diagnosis; the adjustment of the analysis for haema-
turia status and investigation use; the examination of
potential interactions between gender and all other vari-
ables and the use of sensitivity analysis (including for
missing data). Considering generalisability, the sample of
patients was similar to population-based incidence data in
respect of age, sex and cancer;15 and to other primary
care study populations in respect of the proportions of
patients who presented with haematuria (see online
supplementary appendix 3).18 19 21 Further, in supplemen-
tary analysis, we compared the characteristics of 535 par-
ticipating with 2349 non-participating practices and found
trivial differences in practice care quality and patient
experience measures, and small differences for practice
population and team size (see online supplementary
appendix 8).
We believe that the principal reason for improving the
timeliness of cancer diagnosis among symptomatic
patients is to ensure as positive an experience of cancer
care as possible for all patients,9–12 although achieving
such improvements may also help to improve treatment
and prognosis for some. Indeed, there is some evidence
indicating an association between delay and worse onco-
logical outcomes for patients with bladder cancer pre-
senting with haematuria.30 31 For bladder cancer in
particular, women are more likely than men to be diag-
nosed at an advanced stage,32 and there are also
uniquely large gender inequalities in relative survival, as
women have a substantially worse 5-year relative survival
than men (57% vs 44%, respectively).13 While the
median primary care intervals for men and women with
bladder cancer were similar (4 and 6 days, respectively),
there were substantial differences in the tails of the
Table 4 Crude associations and independent predictors of three or more prereferral consultations from the ‘full’ model
(adjusted for gender, age, haematuria status and investigation status)
Crude
odds ratio 95% UCL 95% LCL p Value*
Adjusted
odds ratio 95% UCL 95% LCL p Value*
Bladder (n=740)
Men Reference <0.001 Reference <0.001
Women 2.91 1.93 4.39 3.29 2.06 5.25
16–54 1.52 0.75 3.10 0.23 1.20 0.53 2.72 0.34
55–64 0.68 0.34 1.37 0.59 0.29 1.21
65–74 Reference Reference
75–84 1.32 0.79 2.19 1.18 0.69 2.03
85+ 1.42 0.75 2.66 1.27 0.65 2.49
No haematuria Reference <0.001 Reference <0.001
Haematuria 0.28 0.18 0.42 0.29 0.19 0.46
No blood test Reference <0.001 Reference <0.001
Blood test 2.09 1.39 3.13 2.47 1.58 3.86
No ultrasound scan Reference <0.001 Reference 0.18
Ultrasound scan 2.59 1.50 4.45 1.55 0.82 2.93
Renal (n=287)
Men Reference 0.026 Reference 0.031
Women 1.88 1.08 3.27 1.90 1.06 3.42
16–54 1.17 0.49 2.76 0.99 1.05 0.41 2.74 0.99
55–64 1.04 0.49 2.22 0.85 0.39 1.85
65–74 Reference Reference
75–84 0.95 0.42 2.13 0.95 0.38 2.38
85+ 1.23 0.45 3.36 0.97 0.34 2.77
No haematuria Reference 0.023 Reference 0.25
Haematuria 0.44 0.22 0.89 0.64 0.30 1.37
No blood test Reference 0.001 Reference <0.001
Blood test 2.70 1.54 4.75 2.99 1.64 5.46
No ultrasound scan Reference 0.015 Reference 0.023
Ultrasound scan 2.06 1.15 3.69 2.17 1.11 4.24
*From Wald tests, with joint tests used where applicable.
LCL, lower confidence limit; UCL, upper confidence limit.
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distributions that may have contributed to gender
inequalities in stage and survival, although other factors
such as gender differences in tumour subtypes or other
biological factors may also be responsible.33 These con-
siderations however apply only to bladder cancer; we are
not aware of evidence suggesting substantial gender dif-
ferences in stage and survival from renal cancer.13 The
findings concord with and substantially amplify previous
evidence from patient survey data indicating notable
inequalities in the promptness of diagnosis of women
with bladder and renal cancer (table 1).8 The degree of
concordance of the observed gender inequalities
between national audit and patient-reported data is
remarkable, given the differences in the methodologies
used (see table 5).
The findings signal a large potential for improving the
timeliness of diagnosis of urinary tract cancer in women.
In part, this can be achieved by reinforcement and more
rigorous adherence to existing clinical guidelines on
investigation and management of haematuria.23 Previous
US research indicates that primary care physicians often
do not adhere to guidelines for prompt investigation of
patients presenting with haematuria.34 Interventions to
help general practitioners avoid initial misattribution of
haematuria in women with urinary tract cancer to
benign causes need to be promptly developed and evalu-
ated. Elimination of gender differences in referral deci-
sions in the presence of haematuria would only partially
address overall gender inequalities, although it can help
produce notable improvements with relative ease and
speed. However, because many patients with urinary
tract cancers present without haematuria, research to
better understand these less specific presentations is also
required. The implementation of clinical decision
support tools (ideally combined with evaluation of their
utility) may be helpful, since they incorporate informa-
tion from multiple symptoms, signs and systemic mani-
festations (such as thrombocytosis).20 35 The application
of consultation techniques, such as ‘safety-netting’, the
development of new service models such as outreach
facilities for specialist consultation with urologists and
the development of new tests (eg, based on biomarkers)
are also worthy of exploration and prioritisation of
research investment. Improvements in the sensitivity of
generalist consultations to suspect the presence of uro-
logical cancer among symptomatic patients should reduce
gender inequalities, but should also benefit all patients of
either gender. The positive predictive value of haematuria
for urological cancer is generally lower than 15% (depend-
ing on age),20 and is lower in women than men.21 This
means that even in a hypothetical situation where all
patients presenting to general practitioners with haema-
turia as the main presenting symptom were referred
promptly for specialist investigation, the great majority of
them would be found not to have cancer. Nevertheless,
clinical guidelines, such as those produced by NICE,
mandate the referral of all patients who present with pain-
less macroscopic haematuria independently of their
gender–see also Methods.23 Health economics analyses to
explore the cost-effectiveness of these clinical protocols
may be justified. These realisations can serve as potent
reminders of the need for the development of newer tests
(particularly easily accessible and acceptable point-of-care
tests) and service models.
In conclusion, we report compelling evidence that in
the study setting and during the study period women
with urinary tract cancers were likely to experience a
delayed diagnosis compared with men with the same
cancers. Reinforcing existing guidelines on haematuria
investigation and development of new diagnostic aids for
patients who present without haematuria are needed.
The findings should inform similar investigations in
other country populations.
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